Nicotinamide reduces rate of new nonmelanoma skin cancers in high-risk patients

Nicotinamide, a form of vitamin B3, conferred a 23% reduction in the rate of new, nonmelanoma skin cancers in high-risk patients who previously had skin cancer, according to results from the Australian ONTRAC clinical trial.Nicotinamide — a water-soluble vitamin in the vitamin B group — is affordable and available as an over-the-counter drug in most countries, according to study background.